MedTrace Logo

Insulin Glargine U300 vs Insulin Degludec U100 in Impact on the Glycaemic and Cardiovascular Factors

NCT04692415 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2020-12-31

No results posted yet for this study

Summary

To compare the impact of insulin degludec (IDeg-100) and insulin glargine U300 (IGlar-300) on cardiovascular risk parameters - glycaemic variability (GV), oxidative stress, arterial stiffness and lipid parameters - in insulin naive patients with DMT2.

Conditions

  • Diabetes Mellitus, Type 2

Interventions

DRUG

Degludec

treatment of DM and it's affect on Glycaemic Variability, Oxidative Stress, Arterial Stiffness and the Lipid Profiles

DRUG

Glargine U300

treatment of DM and it's affect on Glycaemic Variability, Oxidative Stress, Arterial Stiffness and the Lipid Profiles

Sponsors & Collaborators

  • Pavle Vrebalov Cindro

    collaborator UNKNOWN

  • Jonatan Vuković

    collaborator UNKNOWN

  • Darko Modun

    collaborator UNKNOWN

  • Božo Smajić

    collaborator UNKNOWN

  • Gordan Kardum

    collaborator UNKNOWN

  • Tina Tičinović Kurir

    collaborator UNKNOWN

  • Doris Rušić

    collaborator UNKNOWN

  • Ana Šešelja Perišin

    collaborator UNKNOWN

  • Josipa Bukić

    collaborator UNKNOWN

  • University of Split, School of Medicine

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-12-15
Primary Completion
2019-06-27
Completion
2019-06-27

Countries

  • Croatia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04692415 on ClinicalTrials.gov